Comparative analysis of serum proteomes of patients with cardiovascular disease

Clinical Biochemistry

Volumn 44, Issue 2-3, 2011, Pages 178-184

  Kim, Hyun Jung ^a   Yoo, Hyun Syuk ^a   Kim, Pan Kyeom ^a   Kim, Mi Ryung ^b   Lee, Hyup Woo ^c   Kim, Chan Wha ^a  

^a Korea University   (South Korea)

^b Silla University   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Biomarkers; Cardiovascular disease; Electrospray ionization quadrupole time of flight; Proteome; RBP4; Two dimensional gel electrophoresis

Indexed keywords

CERULOPLASMIN; HEMOPEXIN; RETINOL BINDING PROTEIN 4; PROTEOME;

ADULT; ARTICLE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROSPRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; CHEMISTRY; METABOLISM; SERUM; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CARDIOVASCULAR DISEASES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; PROTEOME; SERUM; TANDEM MASS SPECTROMETRY;

EID: 79151472174     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.09.027     Document Type: Article

References (42)

1. Reddy K.S., Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998, 97:596-601.
2. Chrysant S.G. Angiotensin ii receptor blockers in the treatment of the cardiovascular disease continuum. Clin Ther 2008, 30(Pt 2):2181-2190.
3. Jin X., Xia L., Wang L.S., Shi J.Z., Zheng Y., Chen W.L., et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics 2006, 6:1948-1956.
4. Giannessi D., Maltinti M., Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007, 56:459-467.
5. Arab S., Gramolini A.O., Ping P., Kislinger T., Stanley B., van Eyk J., et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006, 48:1733-1741.
6. Suzuki T., Nagai R. Cardiovascular proteomic analysis. J Chromatogr B Anal Technol Biomed Life Sci 2007, 855:28-34.
7. Gupta S., Sen S. Myotrophin-kappab DNA interaction in the initiation process of cardiac hypertrophy. Biochim Biophys Acta 2002, 1589:247-260.
8. Duran M.C., Martin-Ventura J.L., Mohammed S., Barderas M.G., Blanco-Colio L.M., Mas S., et al. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. Eur J Pharmacol 2007, 562:119-129.
9. Kofler S., Nickel T., Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci London 2005, 108:205-213.
10. Tsunoda K., Arita M., Yukawa M., Ueyama M., Furuta M., Nakagawa T., et al. Retinopathy and hypertension affect serum high-sensitivity c-reactive protein levels in type 2 diabetic patients. J Diabetes Complications 2005, 19:123-127.
11. Cheung M.C., Brown B.G., Larsen E.K.M., Frutkin A.D., O'Brien K.D., Albers J.J. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Bba Mol Basis Dis 2006, 1762:131-137.
12. Tsutamoto T., Tanaka T., Sakai H., Ishikawa C., Fujii M., Yamamoto T., et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007, 28:1723-1730.
13. Dieplinger B., Gegenhuber A., Poelz W., Haltmayer M., Mueller T. Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 2009, 42:1190-1193.
14. Thongboonkerd V., Chiangjong W., Mares J., Moravec J., Tuma Z., Karvunidis T., et al. Altered plasma proteome during an early phase of peritonitis-induced sepsis. Clin Sci London 2009, 116:721-730.
15. Aldred S., Grant M.M., Griffiths H.R. The use of proteomics for the assessment of clinical samples in research. Clin Biochem 2004, 37:943-952.
16. Chromy B.A., Gonzales A.D., Perkins J., Choi M.W., Corzett M.H., Chang B.C., et al. Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J Proteome Res 2004, 3:1120-1127.
17. Kim H.J., Cho E.H., Yoo J.H., Kim P.K., Shin J.S., Kim M.R., et al. Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 2007, 6:735-743.
18. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
19. Kim H.J., Kim M.R., So E.J., Kim C.W. Comparison of proteomes in various human plasma preparations by two-dimensional gel electrophoresis. J Biochem Biophys Methods 2007, 70:619-625.
20. Shevchenko A., Chernushevich I., Ens W., Standing K.G., Thomson B., Wilm M., et al. Rapid 'de novo' peptide sequencing by a combination of nanoelectrospray, isotopic labeling and a quadrupole/time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 1997, 11:1015-1024.
21. Graham T.E., Yang Q., Bluher M., Hammarstedt A., Ciaraldi T.P., Henry R.R., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-2563.
22. Basualdo C.G., Wein E.E., Basu T.K. Vitamin a (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus. J Am Coll Nutr 1997, 16:39-45.
23. Abahusain M.A., Wright J., Dickerson J.W., de Vol E.B. Retinol, alpha-tocopherol and carotenoids in diabetes. Eur J Clin Nutr 1999, 53:630-635.
24. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
25. Gomez-Ambrosi J., Rodriguez A., Catalan V., Ramirez B., Silva C., Rotellar F., et al. Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass. Clin Endocrinol 2008, 69:208-215.
26. Ueland T., Dalsoren T., Voldner N., Godang K., Henriksen T., Bollerslev J. Retinol-binding protein-4 is not strongly associated with insulin sensitivity in normal pregnancies. Eur J Endocrinol 2008, 159:49-54.
27. Fox P.L., Mukhopadhyay C., Ehrenwald E. Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin. Life Sci 1995, 56:1749-1758.
28. Mukhopadhyay C.K., Mazumder B., Lindley P.F., Fox P.L. Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. Proc Natl Acad Sci USA 1997, 94:11546-11551.
29. Engstrom G., Lind P., Hedblad B., Stavenow L., Janzon L., Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002, 105:2632-2637.
30. Adelstein S.J., Coombs T.L., Vallee B.L. Metalloenzymes and myocardial infarction. I. The relation between serum copper and ceruloplasmin and its catalytic activity. N Engl J Med 1956, 255:105-109.
31. Klipstein-Grobusch K., Grobbee D.E., Koster J.F., Lindemans J., Boeing H., Hofman A., et al. Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study. Br J Nutr 1999, 81:139-144.
32. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
33. Kapojos J.J., Poelstra K., Borghuis T., Banas B., Bakker W.W. Regulation of plasma hemopexin activity by stimulated endothelial or mesangial cells. Nephron Physiol 2004, 96:P1-P10.
34. Cheung P.K., Stulp B., Immenschuh S., Borghuis T., Baller J.F.W., Bakker W.W. Is 100kf an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100kf. J Am Soc Nephrol 1999, 10:1700-1708.
35. Kai H.S., Butler G.S., Morrison C.J., King A.E., Pelman G.R., Overall C.M. Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (timp)-4 and timp-2 c-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the mmp-2 hemopexin c-domain. J Biol Chem 2002, 277:48696-48707.
36. Bakker W.W., Borghuis T., Harmsen M.C., van den Berg A., Kema I.P., Niezen K.E., et al. Protease activity of plasma hemopexin. Kidney Int 2005, 68:603-610.
37. Takagi K., Kin K., Itoh Y., Enomoto H., Kawai T. Human alpha 1-microglobulin levels in various body fluids. J Clin Pathol 1980, 33:786-791.
38. Sullivan D.H., Roberson P.K., Johnson L.E., Mendiratta P., Bopp M.M., Bishara O. Association between inflammation-associated cytokines, serum albumins, and mortality in the elderly. J Am Med Dir Assoc 2007, 8:458-463.
39. Kume N., Kita T. Lectin-like oxidized low-density lipoprotein receptor-1 (lox-1) in atherogenesis. Trends Cardiovas Med 2001, 11:22-25.
40. de Haas CJC New insights into the role of serum amyloid p component, a novel lipopolysaccharide-binding protein. FEMS Immunol Med Microbiol 1999, 26:197-202.
41. Notari L., Baladron V., Aroca-Aguilar J.D., Balko N., Heredia R., Meyer C., et al. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 2006, 281:38022-38037.
42. Takenaka K., Yamagishi S., Matsui T., Nakamura K., Jinnouchi Y., Yoshida Y., et al. Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet pedf in thrombosis of acute coronary syndromes. Atherosclerosis 2008, 197:25-33.